A sensitive and inexpensive high‐resolution melting‐based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

Patients with Down syndrome (DS) are commonly affected by a pre‐leukemic disorder known as transient abnormal myelopoiesis (TAM). This condition usually undergoes spontaneous remission within the first 2 months after birth; however, in children under 5, 20%–30% of cases evolve to myeloid leukemia of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer 2022-11, Vol.69 (11), p.e29866-n/a
Hauptverfasser: Camargo, Ricardo, Castro Moreira dos Santos, Agenor, Cândido Guido, Bruna, Lemos Mendanha Cavalcante, Larissa, Silva Dias, Anna Carolina, Mendonça de Pontes, Robéria, Magalhães Furtado, Felipe, Feitosa Salviano, Cristiane, Tiziani, Valdenize, Martins Córdoba, José Carlos, Quezado Magalhães, Isis Maria
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with Down syndrome (DS) are commonly affected by a pre‐leukemic disorder known as transient abnormal myelopoiesis (TAM). This condition usually undergoes spontaneous remission within the first 2 months after birth; however, in children under 5, 20%–30% of cases evolve to myeloid leukemia of Down syndrome (ML‐DS). TAM and ML‐DS are caused by co‐operation between trisomy 21 and acquired mutations in the GATA1 gene. Currently, only next‐generation sequencing (NGS)‐based methodologies are sufficiently sensitive for diagnosis in samples with small GATA1 mutant clones (≤10% blasts). Alternatively, this study presents research on a new, fast, sensitive, and inexpensive high‐resolution melting (HRM)‐based diagnostic approach that allows the detection of most cases of GATA1 mutations, including silent TAM. The algorithm first uses flow cytometry for blast count, followed by HRM and Sanger sequencing to search for mutations on exons 2 and 3 of GATA1. We analyzed 138 samples of DS patients: 110 of asymptomatic neonates, 10 suspected of having TAM, and 18 suspected of having ML‐DS. Our algorithm enabled the identification of 33 mutant samples, among them five cases of silent TAM (5/110) and seven cases of ML‐DS (7/18) with blast count ≤10%, in which GATA1 alterations were easily detected by HRM. Depending on the type of genetic variation and its location, our methodology reached sensitivity similar to that obtained by NGS (0.3%) at a considerably reduced time and cost, thus making it accessible worldwide.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29866